Novartis, healthcare products manufacturer, acquired Endocyte, a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer, for $24 per fully diluted share in cash. The total deal value is $2.1bn. “The global reach and expertise of Novartis in developing and commercializing RLT therapies will be critical in efforts for patients to benefit from these therapies as quickly as possible.” said Mike Sherman, president and CEO of Endocyte. Centerview Partners LLC is acting as lead financial advisor to Endocyte. Jefferies LLC is also acting as financial advisor to Endocyte. Faegre Baker Daniels LLP is acting as legal counsel to Endocyte.